"Arrr, monoclonal antibodies be makin' waves in the fight against the Sjögren scallywags, me hearties!"
2024-08-05
Arrr, me hearties! The DAHLIAS crew be singin’ shanties o' victory fer nipocalimab and the TWINSS lads be raisin’ a toast fer iscalimab! But alas, poor lusvertikimab be walkin’ the plank! Aye, that’s the way of the seas! <i>Medscape Medical News</i> be spillin’ the beans!
Ahoy, mateys! Gather 'round as I spin ye a yarn 'bout the curious happenings in the realm of potions and elixirs! The DAHLIAS study, like a fine treasure map, led to bountiful results with nipocalimab, makin' our hearts sing like a siren's song! Then there be the TWINSS study, where iscalimab set sail on smooth seas, bringin' forth favorable winds for the crew of science!But lo and behold! A dark cloud loomed over the trial of tibulizumab, yet it too found a glimmer of hope in its phase 1 voyage. Aye, it be a mixed bag of fortunes on that front! However, not all tales be filled with good cheer, for the dastardly lusvertikimab sank like a ship in a stormy sea, bringin' tidings of woe to the crew of researchers. Talk about a hull breach!